Web Exclusives
Web Exclusives — March 18, 2020
COVID-19, the respiratory infection caused by the new coronavirus, is making headlines around the world. Find out what you need to know about this global disease outbreak and how to protect yourself. Read More ›
Web Exclusives — March 17, 2020
Today, more people, including patients diagnosed with chronic lymphocytic leukemia, are living longer with cancer thanks to advancements in cancer treatments. Improvements in the chance for long-term cancer remission are clearly important but living with cancer can also bring a new set of challenges. Read More ›
Web Exclusives — March 17, 2020
People with cancer, including people who have been diagnosed with chronic lymphocytic leukemia, do not need to face it alone. Valuable online and local resources are available for patients with cancer and their loved ones. Read More ›
Web Exclusives — March 17, 2020
For many patients with chronic lymphocytic leukemia (CLL), treatment is personalized. This means that oncologists tailor their medication choices based on the patient’s unique CLL characteristics and medical status. Read More ›
Web Exclusives — March 17, 2020
Targeted therapies are effective in controlling chronic lymphocytic leukemia (CLL). New research is now looking into the impact that these agents can have on autoimmune conditions. Read More ›
Web Exclusives — March 17, 2020
A new type of immunotherapy, allogeneic cord blood–derived CAR NK-cells, could be a future option for patients with chronic lymphocytic leukemia (CLL), based on results from an early-phase clinical trial showing high response rates among patients. Read More ›
Web Exclusives — March 1, 2020
Machines that use artificial intelligence—such as Siri and Alexa—have become part of our everyday lives. Could this technology help in the fight against breast cancer? See how human doctors stacked up against machines in one study. Read More ›
Web Exclusives — February 12, 2020
Ibrutinib is an orally administered Bruton tyrosine kinase inhibitor used in the treatment of patients with CLL. Because ibrutinib has been prescribed in the United States for several years, researchers sought to learn how the rates of side effects in the “real world” compared with those reported in clinical trials. Read More ›
Web Exclusives — February 12, 2020
When treating patients with CLL, understanding specific details about the disease helps doctors as they choose among available treatments. CLL experts believe that conducting specific blood tests before prescribing each patient’s treatment is critical. Do all doctors who treat patients with CLL also appreciate this need for testing? Read More ›
Web Exclusives — February 12, 2020
In a large clinical trial, ibrutinib was shown to be effective in delaying disease progression in patients with early-stage, high-risk CLL who did not yet have symptoms. Researchers are now conducting clinical trials to determine the safety and efficacy of next-generation drugs and combinations in patients with early-stage, high-risk disease. Read More ›